Adherence to Drug Label Recommendations for Avoiding Drug Interactions Causing Statin-Induced Myopathy-A Nationwide Register Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Settergren, Jennifer ^a   Eiermann, Birgit ^b   Mannheimer, Buster ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIBIOTIC AGENT; ATORVASTATIN; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; FELODIPINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERAPAMIL;

ADULT; AGED; ARTICLE; DISEASE REGISTRY; DRUG INTERACTION; DRUG LABELING; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYOPATHY; PRESCRIPTION; PROTOCOL COMPLIANCE; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG LABELING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUSCULAR DISEASES; REGISTRIES; RETROSPECTIVE STUDIES; SWEDEN; YOUNG ADULT;

EID: 84881135658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069545     Document Type: Article

References (53)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
2. Neuvonen PJ, Niemi M, Backman JT, (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565-581.
3. Law M, Rudnicka AR, (2006) Statin safety: a systematic review. Am J Cardiol 97: 52C-60C.
4. Ronaldson KJ, O'Shea JM, Boyd IW, (2006) Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 29: 1061-1067.
5. Jones PH, Davidson MH, (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95: 120-122.
6. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, et al. (2006) Statin safety: an assessment using an administrative claims database. Am J Cardiol 97: 61C-68C.
7. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658-1669.
8. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S, (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24: 429-440.
9. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, et al. (2007) Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 16: 352-358.
10. Lennernas H, (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42: 1141-1160.
11. Neuvonen PJ, Kantola T, Kivisto KT, (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63: 332-341.
12. Kantola T, Kivisto KT, Neuvonen PJ, (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64: 177-182.
13. Kantola T, Kivisto KT, Neuvonen PJ, (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64: 58-65.
14. Jacobson TA, (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94: 1140-1146.
15. Bottorff MB, (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97: 27C-31C.
16. Siedlik PH, Olson SC, Yang BB, Stern RH, (1999) Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39: 501-504.
17. Amsden GW, Kuye O, Wei GC, (2002) A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 42: 444-449.
18. Mousa O, Brater DC, Sunblad KJ, Hall SD, (2000) The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 67: 267-274.
19. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD, (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64: 369-377.
20. Kivisto KT, Kantola T, Neuvonen PJ, (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46: 49-53.
21. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, et al. (2003) The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59: 51-56.
22. Saivin S, Houin G, (1988) Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15: 355-366.
23. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, et al. (2005) Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 28: 223-227.
24. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T, (2000) Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55: 843-852.
25. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ, (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68: 122-129.
26. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ, (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78: 154-167.
27. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, et al. (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69: 340-345.
28. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ, (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73: 538-544.
29. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, et al. (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75: 455-463.
30. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE, (1995) Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76: 80A-83A.
31. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, et al. (2004) Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44: 1054-1062.
32. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, et al. (2000) Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40: 316-323.
33. Gustavson LE, Schweitzer SM, Koehne-Voss S, Achari R, Chira TO, et al. (2005) The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol 45: 947-953.
34. Martin PD, Dane AL, Schneck DW, Warwick MJ, (2003) An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25: 459-471.
35. FASS (the Swedish Physicians' Desk Reference), publisher: Läkemedelsindustriföreningen (LIF), Available: www.fass.se/LIF/home/index.jsp. Accessed December 2011.
36. Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B, et al. (2009) SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65: 627-633.
37. Marie Eliasson PlPPc (2011) Project leader PASCAL. Personal communication, October, 2011.
38. Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, et al. (2007) The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16: 726-735.
39. Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, et al. (2010) Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br J Clin Pharmacol 69: 411-417.
40. WHO Guidelines for ATC classification and DDD assignement. Available: www.whocc.no. Accessed December 2011.
41. Statistiska Centralbyrån (SCB), Statistics Sweden. Available: http://www.scb.se. Accessed November 2011.
42. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J, (1997) Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 53: 7-11.
43. Lau HS, de Boer A, Beuning KS, Porsius A, (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50: 619-625.
44. Ming EE, Davidson MH, Gandhi SK, Marotti M, Miles CG, et al. (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2: 453-463.
45. Bakhai A, Rigney U, Hollis S, Emmas C, (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 5: 485-493.
46. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, et al. (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28: 263-275.
47. Heerey A, Barry M, Ryan M, Kelly A, (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169: 176-179.
48. Devold HM, Molden E, Skurtveit S, Furu K, (2009) Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol 67: 234-241.
49. Eliasson M, Bastholm P, Forsberg P, Henriksson K, Jacobson L, et al. (2006) Janus computerised prescribing system provides pharmacological knowledge at point of care - design, development and proof of concept. Eur J Clin Pharmacol 62: 251-258.
50. Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, von Bahr C, (2008) A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol 64: 1209-1214.
51. Glassman PA, Belperio P, Simon B, Lanto A, Lee M, (2006) Exposure to automated drug alerts over time: effects on clinicians' knowledge and perceptions. Med Care 44: 250-256.
52. Glassman PA, Simon B, Belperio P, Lanto A, (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40: 1161-1171.
53. Ahearn MD, Kerr SJ, (2003) General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software. Med J Aust 179: 34-37.